Biotech Values

[DewDiligence]

At the current share price, PKI has a trailing P/E of about 6. The market for biotech tools and instruments may be weak, but I don’t think it’s as weak as implied by today’s price action. Moreover, a big chunk of PKI’s revenue comes from annuity-like service contracts.